Form 4: TOI Director Karen Johnson Increases Stake

The Oncology Institute, Inc. Director Karen Marie Johnson acquired 84,877 shares of common stock through restricted stock unit grants.

Summary

• Karen Marie Johnson, a Director of The Oncology Institute, Inc. (TOI), reported changes in her beneficial ownership.
• On November 20, 2025, Johnson acquired 47,840 shares of common stock in the form of restricted stock units (RSUs). These RSUs vest in full on the Issuer's 2026 annual stockholder meeting date, contingent on her continued service.
• Also on November 20, 2025, Johnson acquired an additional 37,037 shares of common stock as restricted stock units, which were fully vested upon grant.
• Both acquisitions were at a price of $0, typical for RSU grants.
• Following these transactions, Johnson's direct beneficial ownership of common stock increased to 288,286 shares.

Sentiment

Score: 7

Explanation: The acquisition of additional shares by a director, even through grants, generally indicates confidence in the company's future, which is a positive signal for investors.

Positives

• A Director increasing their stake in the company, even through grants, signals confidence in the company's future prospects.
• The immediate vesting of 37,037 RSUs provides immediate ownership.
• The future vesting of 47,840 RSUs aligns the director's interests with long-term shareholder value.

Negatives

• No negative aspects are directly discernible from this Form 4 filing, which primarily reports compensation-related equity grants.

Risks

• The vesting of 47,840 restricted stock units is subject to continued service with the Issuer through the 2026 annual stockholder meeting date, meaning these shares are not guaranteed if service ceases.

Future Outlook

The future vesting of 47,840 restricted stock units is contingent upon Karen Marie Johnson's continued service with The Oncology Institute, Inc. through the 2026 annual stockholder meeting date, aligning her incentives with the company's long-term performance.

Industry Context

Insider transactions, such as the acquisition of shares by a director, are often viewed by the market as a signal of management's confidence in the company's future performance. These equity grants are a common form of executive and director compensation, designed to align the interests of leadership with those of shareholders.

Related Party Transactions

• The acquisition of common stock through restricted stock unit grants by a director is a related party transaction, representing compensation for service.

Stakeholder Impact

• Shareholders: The increase in director ownership can be seen as a positive signal, suggesting management's belief in the company's value and future growth.
• Employees: Continued service requirements for vesting align director incentives with long-term company stability and performance.

Next Steps

• Karen Marie Johnson's continued service with The Oncology Institute, Inc. until the 2026 annual stockholder meeting date for the vesting of 47,840 restricted stock units.

Key Dates

Recommendation

While the insider acquisition of shares through grants is a positive signal of confidence, a Form 4 filing primarily reports compensation and does not provide sufficient financial or operational details to warrant a 'buy' recommendation without further analysis of the company's fundamentals. It reinforces a 'hold' position for existing investors and suggests a positive indicator for those considering the stock.

Keywords

The Oncology Institute, TOI, Karen Marie Johnson, Director, Insider Transaction, Form 4, Restricted Stock Units, RSU, Beneficial Ownership, Equity Grant